These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 15183078)

  • 1. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
    Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T; Oka K; Ueda H; Imai E
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE-I and ARBs in early diabetic nephropathy.
    Mauer M; Zinman B; Gardiner R; Drummond KN; Suissa S; Donnelly SM; Strand TD; Kramer MS; Klein R; Sinaiko AR
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):262-9. PubMed ID: 12584670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
    Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
    Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S; Aurell M
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats.
    Volpini RA; da Silva CG; Costa RS; Coimbra TM
    Diabetes Metab Res Rev; 2003; 19(1):43-51. PubMed ID: 12592643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients.
    Deyneli O; Yavuz D; Velioglu A; Cacina H; Aksoy N; Haklar G; Taga Y; Akalin S
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7(2):98-103. PubMed ID: 17083064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
    Mifsud SA; Allen TJ; Bertram JF; Hulthen UL; Kelly DJ; Cooper ME; Wilkinson-Berka JL; Gilbert RE
    Diabetologia; 2001 Jul; 44(7):878-82. PubMed ID: 11508273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure].
    Vizir VA; Berezin AE
    Ter Arkh; 2002; 74(1):52-5. PubMed ID: 11878061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition.
    Sassy-Prigent C; Heudes D; Jouquey S; Auberval D; Belair MF; Michel O; Hamon G; Bariety J; Bruneval P
    Lab Invest; 1995 Jul; 73(1):64-71. PubMed ID: 7603042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation.
    Hagiwara S; Makita Y; Gu L; Tanimoto M; Zhang M; Nakamura S; Kaneko S; Itoh T; Gohda T; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2006 Mar; 21(3):605-15. PubMed ID: 16282336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
    Renke M; Tylicki L; Rutkowski P; Rutkowski B
    Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.